Alex A. Cordi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex A. Cordi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Newman-Tancredi
Neurolixis SAS, 2 rue Georges Charpak, 81100 Castres, France
1 shared publication Anita Roger
Institut de Recherches Servier, 125, chemin de Ronde, 78290 Croissy, France
1 shared publicationAstrid G. Chapman
Department of Neurology, Institute of Psychiatry, de Crespigny Park, London SE5 8AF, United Kingdom
1 shared publicationBrian S. Meldrum
Department of Neurology, Institute of Psychiatry, de Crespigny Park, London SE5 8AF, United Kingdom
1 shared publicationClaude Fugier
ORIL Industrie, 13, rue Auguste Desgenetais, BP 17, 76210 Bolbec, France
1 shared publicationElisabeth Ruano
Institut de Recherches Servier, 11, rue des Moulineaux, F-92150 Suresnes, France
1 shared publication
Latest Publications
- 1 September 2002
- Published by Elsevier in Il Farmaco
- Vol. 57 (10) , 787-802
Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity
- 1 September 2002
- Published by Elsevier in Il Farmaco
- Vol. 57 (10) , 787-802
Novel quinolinone-phosphonic acid AMPA antagonists devoid of nephrotoxicity
- 3 February 2001
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (5) , 787-805
Potential Antidepressants Displayed Combined α2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties
Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metabolism (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3−6 weeks) before robust clinical efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic α2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic α2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two molecules have been described with such a pharmacological profile. Of these, napamezole (2) was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole (4a), which displayed the desired profile: α2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original molecule, a series of derivatives was designed and synthesized, encompassing substituted as well as rigid analogues. Structure−activity relationships permitted the selection of 14c (4(5)-[(5-fluoroindan-2-yl)methyl]-4,5-dihydroimidazole) as a development candidate.
- 3 February 2001
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (5) , 787-805
Potential Antidepressants Displayed Combined α2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties
Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metabolism (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3−6 weeks) before robust clinical efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic α2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic α2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two molecules have been described with such a pharmacological profile. Of these, napamezole (2) was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole (4a), which displayed the desired profile: α2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original molecule, a series of derivatives was designed and synthesized, encompassing substituted as well as rigid analogues. Structure−activity relationships permitted the selection of 14c (4(5)-[(5-fluoroindan-2-yl)methyl]-4,5-dihydroimidazole) as a development candidate.